Retatrutide vs Tirzepatide
Retatrutide and tirzepatide are both incretin-based peptides, but they engage different numbers of receptors. This page sets out the pharmacological difference without claiming superiority for either molecule.
Key concepts
- Tirzepatide: GIP + GLP-1. Retatrutide: GIP + GLP-1 + glucagon
- The pair is a useful matched probe for glucagon receptor contribution
- Comparisons in the literature are largely indirect
- Maturity of evidence differs from pharmacological difference
- Comparative assays should use identical format and reference agonists for both peptides
- Testing only in incretin-only systems will miss the glucagon receptor contribution
- Matched handling, storage and certificates of analysis reduce confounds in comparative studies
- The isolated contribution of glucagon receptor activity remains an open, unresolved question
The core difference
Tirzepatide is a dual agonist at the GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity to those two. That single addition is the substantive pharmacological difference between them, and everything else follows from it.
Both are long-acting, fatty-acid-modified peptides designed for weekly rather than daily study schedules, and both are supplied for laboratory work as lyophilised powders requiring reconstitution.
What the difference implies for experiments
In a model expressing only GLP-1 and GIP receptors, the two peptides are asking a similar question. In a hepatocyte model, or any system expressing glucagon receptors, they are not: only retatrutide has a direct pharmacological route into that tissue.
This makes the pair useful as a matched comparison. Holding the incretin arm roughly constant and adding glucagon receptor activity is close to a controlled way of asking what that third receptor contributes.
State of the comparative evidence
Direct head-to-head clinical comparisons between retatrutide and tirzepatide are limited. Most comparisons in circulation are indirect — separate trials with different populations, designs and endpoints — and indirect comparison is a weak basis for claims about relative effect size.
Tirzepatide additionally has a substantially longer and more mature clinical record, including phase 3 programmes, whereas retatrutide’s public record is at an earlier stage. Differences in the depth of evidence should not be read as differences in pharmacology, or the reverse.
Side-by-side summary
The table below is a study-design aid, not a claim of relative merit. Exact potency and pharmacokinetic figures should always be confirmed against the primary pharmacology papers rather than read from a summary table.
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Research designation | LY3298176 | LY3437943 |
| Receptor targets | GIP, GLP-1 | GIP, GLP-1, glucagon |
| Lipidation strategy | C20 fatty di-acid, albumin binding | Fatty-acid modification, albumin binding |
| Clinical evidence stage | Phase 3 and post-marketing literature | Phase 2 and earlier |
| UK regulatory status | Investigational as supplied here; not for human use | Investigational; not for human use |
Designing a comparative experiment
A well-designed comparison between the two peptides holds assay format, cell background, reference agonist and concentration range identical across both molecules, and reports results from both GIP/GLP-1-only systems and glucagon-receptor-bearing systems separately. Testing only in a system that lacks glucagon receptors will understate any real difference between the two compounds.
Where a laboratory wants to isolate the glucagon receptor contribution specifically, running tirzepatide as the matched dual-agonist control alongside retatrutide is the most direct experimental design available in this peptide family, though it still assumes the incretin arms of the two molecules behave equivalently, which itself should be verified rather than assumed.
Analytical and handling parity
Because both peptides are supplied as lyophilised, fatty-acid-modified proteins, a fair comparative study also holds analytical and handling variables constant: the same reconstitution diluent and concentration, matched storage temperature and duration prior to use, and independently verified certificates of analysis for both batches confirming purity by HPLC and identity by mass spectrometry. Differences in handling history between the two vials are a plausible confound that is easy to overlook when the pharmacological difference between the molecules is the intended focus.
Where a laboratory cannot source both peptides from batches manufactured and tested to the same analytical standard, that limitation should be reported alongside any comparative result, since apparent differences in potency or efficacy could otherwise reflect batch quality rather than receptor pharmacology.
What remains unresolved
The central open question in this comparison is not which molecule is more potent overall, but what the addition of glucagon receptor activity contributes once the incretin arm is held constant, and under what conditions that contribution is beneficial, neutral or counterproductive to a given endpoint. Indirect cross-trial comparisons cannot resolve this because the two clinical programmes differ in population, duration and endpoint definitions as well as in molecule.
Until well-controlled, matched head-to-head data are available, any claim ranking the two compounds against each other should be treated as provisional, and readers are encouraged to trace such claims back to the specific study design that produced them rather than accepting a summary at face value.
Strength of the current evidence
Receptor-level differences are well documented. Comparative clinical claims are not supported by head-to-head evidence and should be treated as open questions.
References
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
- Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Molecular Metabolism, 2018 (PubMed)
Related Retatrutide research
- Triple Receptor Agonism — What triple receptor agonism means in peptide design, and how balance between receptors is characterised.
- Mechanism of Action — How retatrutide engages the GIP, GLP-1 and glucagon receptors, and what that combined signalling is understood to do.
- Published Research — An overview of the peer-reviewed retatrutide research record, from receptor pharmacology to phase 2 trials.
- What is Retatrutide? — Definition, research designation, peptide class and receptor targets of retatrutide as a laboratory research compound.
Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis
Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.